Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Yun Zhong reiterated a Buy rating on Opus Genetics with an unchanged $10 price target, citing the upcoming OPGx-BEST1 data readout in September as a key catalyst. JonesTrading also maintained a Buy rating with a $10 target. Analysts view positive efficacy signals or dose escalation justification from the data as favorable outcomes, supported by encouraging early safety and vision improvement results.
Wedbush analyst Yun Zhong maintained a Buy rating on Opus Genetics today and set a price target of $10.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Yun Zhong has given his Buy rating due to a combination of factors, including the upcoming three-month data readout for OPGx-BEST1 in September, which he views as a pivotal value inflection point. He believes either a strong efficacy signal enabling a pivotal conversion at the current dose, or a moderate effect that justifies dose escalation, would both be favorable outcomes given the limited competitive landscape and high patient interest.
He also highlights encouraging early results from the sentinel ARB patient, where safety, vision improvement, and fluid resolution collectively support a high probability of meaningful benefit across the first cohort. In addition, he points to Opus’ broader gene therapy platform and the recent regulatory alignment on OPGx-LCA5 as reinforcing the company’s long-term growth prospects, underpinning his unchanged $10 price target and continued Buy recommendation.
Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Wave Life Sciences, and Opus Genetics. According to TipRanks, Zhong has an average return of -6.1% and a 41.64% success rate on recommended stocks.
In another report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $10.00 price target.